Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Significant Growth in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a large increase in short interest in July. As of July 15th, there was short interest totaling 802,797 shares, an increase of 10,237.3% from the June 30th total of 7,766 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average trading volume of 544,670 shares, the days-to-cover ratio is presently 1.5 days.

Provectus Biopharmaceuticals Price Performance

Shares of PVCT opened at $0.06 on Friday. Provectus Biopharmaceuticals has a 1 year low of $0.04 and a 1 year high of $0.10. The company’s 50-day simple moving average is $0.06 and its 200-day simple moving average is $0.06.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.